/PRNewswire/ AUM Biosciences (AUM) today announced the successful completion of USD $27 million series A funding round. This will fuel AUM s vision of.
Ramesh Subrahmanian joins Everlife Board prnewswire.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.co.uk Daily Mail and Mail on Sunday newspapers.
Senior Editor
Princeton, N. J.-based Slayback Pharma is shoring up its generics and specialty pipeline. The company on Wednesday announced that The Everstone Group is investing up to $50 million in Series B funding.
The new capital will be used to expand and accelerate further Slayback s pipeline of complex generic and specialty pharmaceutical products, Slayback said.
In addition to the investment, Everstone managing directors Arjun Oberoi and Puncham Mukim will join Slayback s board of directors. Everstone joins existing institutional investor KKR, who first invested in Slayback with a $60 million commitment in December 2016. We are delighted to partner with Everstone in our quest for smart solutions to complex pharmaceutical challenges. Their experience in investing in and building pharmaceutical businesses with a focus on regulated markets will help turbo-charge our growth pipeline of complex and specialty products. We are especially thrilled to welcome Arjun an